drugset / Trial / NCT04906434

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

NCT04906434

Phase 1 Recruiting 200 enrolled Abbisko Therapeutics Co, Ltd
NaSequentialOpen-labelTreatment

Summary

This is an open-label phase 1 study with an escalation part and an expansion part.

Timeline

Start
2020-02-26
Primary completion
2027-12-31
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject ABSK-011 Unknown Oral

Indications